Company Overview
Moderna, Inc. operates as a biotechnology entity dedicated to the development and delivery of messenger RNA medicines across the United States, Europe, and international markets, with a specific focus on respiratory vaccines and latent vaccine candidates. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself to capitalize on advancements in genetic medicine and immunology. Its current scale is defined by a market capitalization of $20.68B, an annual revenue of $1.94B, and an workforce comprising 4700 employees. These valuation and revenue figures indicate that the company maintains a significant presence in the pharmaceutical landscape, yet the negative year-over-year revenue growth of 29.8% suggests a challenging environment for maintaining its current scale and market position relative to prior performance periods.
Financial Health
The financial statements reveal a complex structure where revenue of $1.94B generated a net income of $-2,822,000,128 and an EBITDA of $-2,859,000,064, highlighting a substantial gap between top-line sales and bottom-line profitability. This disparity indicates that the company's cost structure involves significant operating expenses that exceed gross revenues, resulting in a gross margin of -105.8%, an operating margin of -126.4%, and a profit margin of -145.2%. The negative values across all three margins suggest that the company is currently burning cash to fund research, development, and commercialization efforts rather than generating operational profits. Free cash flow stands at $-1,326,499,968, which reflects a consumption of liquidity that limits immediate financial flexibility for share buybacks or aggressive expansion without external capital. Despite these outflows, the balance sheet holds $5.80B in cash against $1.30B in debt, creating a net cash position that provides a buffer against short-term obligations. The debt-to-equity ratio of 15.09 indicates a leveraged capital structure relative to equity, yet the high current ratio of 3.29 demonstrates robust short-term liquidity and the ability to cover current liabilities with current assets. Return on Equity is -28.9% and Return on Assets is -14.5%, metrics that reveal that management effectiveness in generating returns is currently negative, a common characteristic for biotechnology firms in early or transitional growth phases before product cycles mature.
Valuation Assessment
Valuation metrics for the company are constrained by its lack of positive earnings, as evidenced by a trailing P/E ratio of N/A and a forward P/E of -11.51. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in future earnings recovery expectations rather than historical profitability. A price-to-book ratio of 2.39 indicates that the market assigns a premium to the company's intangible assets, intellectual property, and future pipeline potential over its tangible book value. Alternative valuation metrics such as the price-to-sales ratio of 10.64 and an EV/EBITDA of -5.66 suggest that the stock is being valued primarily on revenue generation and asset backing rather than current cash earnings. Price metrics show a 52-week high of $59.55 and a 52-week low of $22.28, placing the current trading price somewhere within this volatile range depending on the specific share price at the time of analysis. The beta value of 1.35 indicates that the stock price is more volatile than the broader market, moving 35% more than the general index in response to market fluctuations.
Growth & Income
The company reports a revenue growth rate of -29.8% year-over-year, while earnings growth is listed as N/A due to the absence of positive earnings in the trailing twelve months. Since earnings are negative, they are not growing faster than revenue in a traditional sense, but rather the company is facing contraction in top-line sales which exacerbates the deficit in net income. Regarding dividends, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute cash to shareholders. This approach implies that the company retains all available cash to reinvest into its mRNA pipeline and operational needs rather than paying dividends. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting a strategy focused on capital appreciation through future product success rather than current yield.